A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Exclusion criteria

• . Prior treatment with anti-CD70 targeting agents
• . Active CNS manifestation of underlying disease
• . History or presence of clinically relevant CNS pathology such as seizure, stroke, severe brain injury, cerebellar disease, myelopathy, history of posterior reversible encephalopathy syndrome with prior therapy, or another condition that in opinion of investigator may increase CAR T-related toxicities
• . Uncontrolled bacterial, viral, or fungal infection
• . Positive for HIV, or active hepatitis B virus or hepatitis C virus infection.
• . Concurrent systemic treatment with an anticancer biologic (e.g., monoclonal antibody) within 30 days prior to CTX131 infusion or with a non-biological anticancer drug within 14 days prior to CTX131 infusion. Mogamulizumab treatment is prohibited 50 days prior to CTX131 infusion.
• . Diagnosis with another invasive malignancy in the last 5 years with the exception of non- melanoma skin cancer and malignancies deemed by the investigator and medical monitor to be of low likelihood for recurrence
• . Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.